Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Pancreatic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urinary Bladder Neoplasms 1Turcot syndrome 1Stomach Neoplasms 1Oligoprogressive 1Neoplasms 1Neoplasm Metastasis 1Lymphatic Metastasis 1Lung Neoplasms 1Head and Neck Carcinoma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Breast Cancer Patients 1

Interventions

pembrolizumab 157Gemcitabine 140Capecitabine 123Paclitaxel 121Fluorouracil 117Oxaliplatin 110Bevacizumab 106Nivolumab 99Docetaxel 98Leucovorin 97Cisplatin 90Radiosurgery 88Irinotecan 88Carboplatin 86Cyclophosphamide 72Cetuximab 72Magnetic Resonance Spectroscopy 68Specimen Handling 60Radiotherapy 60Trastuzumab 59Biopsy 59Ipilimumab 53Drug Therapy 51Everolimus 48Pemetrexed 46Albumin-Bound Paclitaxel 45130-nm albumin-bound paclitaxel 44Doxorubicin 42Fulvestrant 40aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasm Metastasis × DEAE-Dextran × Clear all
NCT06712745 2025-11-10

Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung

University of Texas Southwestern Medical Center

Phase EARLY_PHASE1 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡